HAA方案诱导治疗老年初发急性髓系白血病20例疗效观察

Observation on the therapeutie effect of HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia in the elderly

目的:观察高三尖杉酯碱(HHT)、阿糖胞苷(Ara-C)、阿克拉霉素(Acla)三药联合(HAA)方案对老年初发急性髓系白血病(AML)的疗效。方法:老年初发AML患者20例,以HAA方案进行诱导化疗,观察其有效率和不良反应。结果:20例老年AML患者中完全缓解(CR)14例(占70%),其中一疗程CR 12例(占60%),部分缓解(PR)2例(占10%),总有效率达80%。结论:HAA方案可以作为一般状况良好的初治老年AML患者的有效治疗方案,其不良反应可以耐受。

Objective： To analyse the treatment outcome of 20 newly diagnosed acute myeloid leukemia （AML） in the elderly patients, and explore the efifcacy and safety of HAA regimen, which consisting of homo-harringtonine （HHT）, cytarabine （Ara-C） and aclarubicin （Acla）.Methods： All of the patients enrolled were treated with HAA regimen. The complete remission （CR） rate was observed.Results： Out of the 20 patients, 14 （70%） attained CR and the ifrst single course of this induction regimen resulted in a CR rate of 60%. The main side effects included myelosuppression, infections and gastrointestinal disorders. These side effects improved by support and anti-infection therapy and generally did not affect the treatment.Conclusion： HAA regimen is a safe regimen and it is efifcacious, well-tolerable induction therapy for newly diagnosed AML in the elderly. A high CR rate can be achieved with only one or two courses of this regimen.